Japanese API Manufacturer to Remain on Import Alert for CGMP Violations
The Food and Drug Administration will continue to refuse imports of active pharmaceutical ingredients (API) manufactured by Japanese company Asada Milling Co., Ltd.’s facility in Kanra, Japan, it said in a warning letter. The products at the facility were already…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
subject to import alert for current good manufacturing practice violations. The company failed to correct the problems, FDA said.